What happened with RDY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Dr. Reddy’s Laboratories is an India-based pharmaceutical company whose Global Generics business brings in most of its revenue. It makes prescription and over-the-counter medicines, including alternatives to branded drugs that deliver equivalent treatment. Retail chains, wholesalers and private-label customers buy most of its North American generics; elsewhere, it also sells through distributors, pharmacies and hospitals. North America is its largest finished-medicines market. Its consumer business includes smoking-cessation products sold outside the United States, led by Nicotinell, mainly through pharmacies and retailers.
A smaller business supplies other drugmakers with active pharmaceutical ingredients—the substances that give medicines their therapeutic effect—and intermediates used to make them. It also supplies ingredients for its own medicines. Through Aurigene Pharmaceutical Services, it earns fees for helping pharmaceutical and biotechnology companies discover, develop and manufacture drugs.
The generics business depends on getting new products approved and launched before competing suppliers drive down prices. Concentrated purchasing power among North American buyers also pressures prices. Regulators require evidence that generic medicines match branded drugs and that factories meet quality standards; failures can block approvals or imports. Patent rights can also delay launches or prevent sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Dr. Reddy’s results hinge on launching generics before rivals and managing falling prices, so also watch Sandoz and Sun Pharmaceutical Industries, which are absent from this list.
Teva competes with Dr. Reddy’s in U.S., European and Russian generics, and both sell drug ingredients to pharmaceutical manufacturers. Watch Teva’s generic launches and pricing: earlier rival launches can erode Dr. Reddy’s sales and gross profit.
Viatris competes with Dr. Reddy’s for U.S. generic-drug buyers across tablets and capsules, injectables and complex medicines. Its U.S. pricing and supply reliability offer a read on the competition facing Dr. Reddy’s sales to retail chains and wholesalers.
Amneal Pharmaceuticals, Inc. competes with Dr. Reddy’s in U.S. retail generics, injectables and biosimilars sold into retail and institutional markets. Watch launches in Amneal’s Affordable Medicines business, especially technically difficult products: new competitors can reduce Dr. Reddy’s market share and margins.
Dr. Reddy’s sells generic lenalidomide against Bristol Myers Squibb’s Revlimid, and their patent settlement shaped generic entry and competition. Watch the U.S. antitrust cases challenging that settlement; lenalidomide price declines already contributed to Dr. Reddy’s underlying revenue decline in the year ended March 31, 2026.
Perrigo competes with Dr. Reddy’s to supply U.S. retailers with medicines sold under their own store brands, while its NiQuitin competes with Dr. Reddy’s nicotine-replacement brands. Watch Perrigo’s store-brand pricing and NiQuitin performance for pressure on Dr. Reddy’s OTC and smoking-cessation businesses.
Dr. Reddy’s depends on Alvotech’s development and supply capabilities for their denosumab biosimilar partnership in the United States and Europe; Alvotech earns payments from partners that market and sell its products. Watch the AVT03 patent litigation, because an adverse ruling could affect their access to the U.S. market.
Kenvue’s Nicorette competes for smoking-cessation customers with Dr. Reddy’s Nicotinell-led nicotine-replacement portfolio outside the United States. Watch Nicorette’s market share: Dr. Reddy’s nicotine-replacement business accounted for 51% of its European Global Generics sales in the year ended March 31, 2026.
Amphastar Pharmaceuticals, Inc. competes with Dr. Reddy’s in technically challenging injectable medicines, a market where Dr. Reddy’s sells through wholesalers, clinics and hospitals. Watch Amphastar’s injectable approvals and launches for new competition facing Dr. Reddy’s oncology and critical-care injections.
ANI Pharmaceuticals, Inc. and Dr. Reddy’s compete for U.S. pharmaceutical buyers with broad generic portfolios, including differentiated formulations. Watch ANI’s new launches in products such as modified-release and hormonal medicines, where its manufacturing capabilities help it enter niches with fewer generic competitors.
Dr. Reddy's Laboratories Limited earningsThis company
Dr. Reddy’s report will show whether price erosion in its generics business is still outweighing growth in Europe, India and emerging markets, and squeezing profit.
Read Global Generics sales alongside its gross-profit margin. Sales growth with a steadier margin would show launches and growth in Europe, India and emerging markets are offsetting price cuts. Weaker sales and a further margin decline would show price pressure on existing products is still outpacing growth, leaving less profit cushion.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show how Revlimid sales bear on the U.S. market and pricing room for Dr. Reddy’s generic lenalidomide.
Look at Bristol Myers Squibb’s Revlimid sales trend and what it says about generic competition. Steady sales would show demand for the branded drug remains, leaving a market for Dr. Reddy’s generic to compete in—but not proving it can hold its price. A sharp decline would point to a shrinking market that could also weigh on generic sales. The report alone cannot attribute the change to generics or the settlement litigation.
